ArticlePharmaceutical nanotechnology2026
High Flavonoid Content in
Article in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimTo develop medicinal plant nanoparticles as colitis alternative/supplementary therapy.
backgroundLimited reports about the effectiveness of medicinal plant nanocrystals in treating or preventing colitis.
objectivesWe investigated the effect of nanonizing Apium graveolens (AG) on improving dextran sodium sulfate (DSS)- induced colitis.
methodsNanonization was performed via the bead milling process. The nanocrystal product was characterized (i.e., particle size, zeta potential (ZP), polydispersity index (PDI) values) and freezedried. Total flavonoids and phenolic compounds in nanocrystal products were compared with ethanolic extract of AG (AGEE). Anti-colitis activity of AG-nanocrystal water suspensions (AGNS) was compared to AG bulk powder suspensions (AGBS). Colitis severity was determined via physiological, macroscopic, and microscopic colon assessment. In addition, the fecal Enterobacteriaceae population and urine glucose levels were determined. RESULTS AND DISCUSSION: The AG nanoparticle products are 200-400 nm, with PDI values 0.5-0.6, and ZP values -12 to -20 mV. The total flavonoid and phenolic compounds of AGNS were 115.12±4.32 ppm and 37.11±0.34 ppm, respectively. This value is higher compared to the content in AGEE. AGNS (350 mg/kg) improves physiological (i.e., fecal blood), macroscopic (i.e., length, diameter), and microscopic (i.e., structure and immune cell infiltration) colon conditions in a comparable level to the positive control of 5-aminosalicylic acid (100 mg/kg). AGNS have a compelling ability to restore colon microscopic and Enterobacteriaceae population compared to AGBS (700 mg/kg). AGNS (350 mg/kg) also recovered colon permeability as marked by the lower urine glucose concentration (9.90±0.15 mg/dL) compared to colitis mice (12.43±0.09 mg/dL).
conclusionThe nanonization of AG contributes to improved anti-colitis activities compared to AGBS. Nanonization of medicinal plants will reduce organic solvent extraction, which supports the sustainable development goals.
Indexed as
Identifiers
40357786What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.